EU/3/05/271: Orphan designation for the treatment of visceral leishmaniasis

Paromomycin sulfate

Table of contents


Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in March 2011 on request of the sponsor.

On 11 April 2005, orphan designation (EU/3/05/271) was granted by the European Commission to OneWorld Health, United Kingdom, for paromomycin sulfate for the treatment of visceral leishmaniasis.

The sponsorship was transferred to Sestria Ltd, United Kingdom, in November 2009.

Key facts

Active substance
Paromomycin sulfate
Intended use
Treatment of visceral leishmaniasis
Orphan designation status
EU designation number
Date of designation
Sestria Ltd
88 High Street North
Bedfordshire LU7 0EW
United Kingdom
Telephone: +44 7794 265 473
Telefax: +44 1525 240 504

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating